Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026

VERACYTE, INC.

Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.
Compensation includes $500,000 base salary, 55% target bonus, RSUs and PSUs each valued at $1.5 million.
RSU vests over four years; PSU vests upon achievement of performance objectives set by Compensation Committee.
No family relationships or material transactions with the company or its other officers disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.